Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROC trial of induction DCF chemoselection for organ preservation in stage II/III esophageal squamous cell carcinoma
jRCTs031180380Phase 2Active, not recruiting
- Sponsor
- Yakult Honsha
- Start
- Jul 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel, cisplatin and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Yakult Honsha. Primary endpoint: Progression-free survival at 1 year in patients treated with chemoradiotherapy. Started Jul 2012; status: active, not recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCTs031180380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180380.